80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

Core Insights - Evaxion Biotech A/S has announced new data highlighting the effectiveness of its personalized cancer vaccine EVX-01 in generating a targeted immune response against advanced melanoma [1][4] - The ongoing phase 2 trial of EVX-01 shows an 80% tumor-specific immune response rate, an improvement from previous rates of 71% and 79% reported at earlier conferences [2][3][9] - The trial is set to provide two-year clinical data in the second half of 2025, with an extension allowing for a more comprehensive evaluation of EVX-01's potential [5] Company Overview - Evaxion Biotech A/S specializes in AI-Immunology™ powered vaccines, focusing on personalized treatments for cancer and other diseases [1][12] - The company’s lead clinical asset, EVX-01, is designed to target the unique tumor profiles of individual patients, enhancing the immune system's ability to combat cancer [10][8] Clinical Trial Details - The phase 2 trial investigates EVX-01 in combination with Merck's KEYTRUDA® (pembrolizumab) for patients with advanced melanoma [6] - The trial has demonstrated overall response rates of 69% and 67% in previous analyses, indicating a strong correlation between clinical responses and AI-Immunology™ predictions [11] Presentation Information - New immune data will be presented at the AACR Annual Meeting, with details including the abstract title and session information [7]